AlzeCure Pharma Management

Management criteria checks 3/4

AlzeCure Pharma's CEO is Martin Jönsson, appointed in Jan 2020, has a tenure of 4.83 years. total yearly compensation is SEK2.48M, comprised of 76.6% salary and 23.4% bonuses, including company stock and options. directly owns 0.46% of the company’s shares, worth €38.20K. The average tenure of the management team and the board of directors is 4.8 years and 3.5 years respectively.

Key information

Martin Jönsson

Chief executive officer

SEK 2.5m

Total compensation

CEO salary percentage	76.6%
CEO tenure	4.8yrs
CEO ownership	0.5%
Management average tenure	4.8yrs
Board average tenure	3.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Martin Jönsson's remuneration changed compared to AlzeCure Pharma's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	-SEK 36m
Jun 30 2024	n/a	n/a	-SEK 36m
Mar 31 2024	n/a	n/a	-SEK 37m
Dec 31 2023	SEK 2m	SEK 2m	-SEK 37m
Sep 30 2023	n/a	n/a	-SEK 38m
Jun 30 2023	n/a	n/a	-SEK 42m
Mar 31 2023	n/a	n/a	-SEK 53m
Dec 31 2022	SEK 2m	SEK 2m	-SEK 56m
Sep 30 2022	n/a	n/a	-SEK 68m
Jun 30 2022	n/a	n/a	-SEK 73m
Mar 31 2022	n/a	n/a	-SEK 67m
Dec 31 2021	SEK 2m	SEK 2m	-SEK 78m
Sep 30 2021	n/a	n/a	-SEK 73m
Jun 30 2021	n/a	n/a	-SEK 78m
Mar 31 2021	n/a	n/a	-SEK 81m
Dec 31 2020	SEK 2m	SEK 1m	-SEK 71m

Compensation vs Market: Martin's total compensation ($USD225.04K) is below average for companies of similar size in the German market ($USD472.15K).

Compensation vs Earnings: Martin's compensation has increased whilst the company is unprofitable.

CEO

Martin Jönsson (56 yo)

4.8yrs

Tenure

SEK 2,475,000

Compensation

Mr. Martin Jönsson is the Chief Executive Officer of AlzeCure Pharma AB (publ) since January 8, 2020. Mr. Jönsson served in a senior position at Ferring Pharmaceuticals in the US, he was business area dire...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Martin Jönsson	Chief Executive Officer	4.8yrs	SEK 2.48m	0.46% € 38.2k
Birgitta Lundvik	Chief Financial Officer	7.8yrs	no data	0.14% € 11.4k
Johan Sandin	Chief Scientific Officer	4.8yrs	SEK 1.28m	0.99% € 81.7k
Marta Storck	Chief Medical Officer & Head of Development	3.6yrs	no data	0.084% € 6.9k
Pontus Forsell	Head of Research & Discovery	7.8yrs	no data	1.03% € 84.7k

4.8yrs

Average Tenure

57yo

Average Age

Experienced Management: AC6's management team is considered experienced (4.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Thomas Pollare	Chairman	7.8yrs	SEK 229.00k	1.7% € 140.1k
Jan Lundberg	Director	less than a year	no data	no data
Ragnar Linder	Independent Director	7.8yrs	SEK 115.00k	0.056% € 4.6k
John Harrison	Scientific Advisor	no data	no data	no data
Bengt Winblad	Scientific Advisor	no data	no data	no data
Peter Snyder	Scientific Advisor	no data	no data	no data
Henrik Zetterberg	Scientific Advisor	no data	no data	no data
Rolf Karlsten	Scientific Advisor	no data	no data	no data
Janet Hoogstraate	Independent Director	1.5yrs	SEK 73.00k	0.028% € 2.3k
Sven Ogren	Scientific Advisor	no data	no data	no data
Eva Lilienberg	Independent Director	3.5yrs	SEK 115.00k	0.0028% € 233.1

3.5yrs

Average Tenure

70yo

Average Age

Experienced Board: AC6's board of directors are considered experienced (3.5 years average tenure).

AlzeCure Pharma Management

Management criteria checks 3/4

Key information

Recent management updates

AlzeCure Pharma AB (publ) Approves the Election of Jan Lundberg as New Ordinary Members of the Board of Directors

AlzeCure Pharma AB (publ) Approves the Election of Jan Lundberg as New Ordinary Members of the Board of Directors

AlzeCure Pharma AB (publ) Appoints Janet Hoogstraate to its Board

Chief Executive Officer recently bought €16k worth of stock

Chief Executive Officer recently bought €16k worth of stock

AlzeCure Pharma AB (publ), Annual General Meeting, May 12, 2021

Recent updates

AlzeCure Pharma AB (publ) Presents New Positive Data for the TrkA-NAM Pain Project Against Osteoarthritis

AlzeCure Pharma AB (publ) to Report Q2, 2025 Results on Aug 26, 2025

AlzeCure Pharma AB (publ) Announces an Abstract with Preclinical Data on NeuroRestore ACD856 Demonstrating Its Anti-In-In-In-Class Drug Candidate for Alzheimer's Disease

AlzeCure Pharma AB (publ) Announces New Results from Alzecure's Pain Project TrkA- NAM Presented At the Pain Conference IASP 2024

New minor risk - Shareholder dilution

Alzecure Pharma AB (Publ) Announces Positive Clinical Results with Painless ACD440 Against Neuropathic Pain

AlzeCure Pharma AB (publ) Approves the Election of Jan Lundberg as New Ordinary Members of the Board of Directors

AlzeCure Pharma AB (publ) Approves the Election of Jan Lundberg as New Ordinary Members of the Board of Directors

New minor risk - Financial position

AlzeCure Pharma AB (publ) Presents New Data Regarding the TrkA-NAM Pain Project at IASP 2024

New major risk - Market cap size

AlzeCure Presents New Preclinical Data with NeuroRestore ACD856 at Leading Alzheimer's Conference

AlzeCure Pharma AB (publ) Publishes Clinical Results Supporting Continued Development of NeuroRestore ACD856 Against Alzheimer's

New major risk - Revenue and earnings growth

AlzeCure Pharma AB (publ) Gets Late Breaking Abstract of New Preclinical Data with ACD856 Accepted at AD/PD 2024 Conference

AlzeCure Pharma AB (publ) Selects Drug Candidate and Enters Next Phase of Development with Trka-Nam Acd137 Against Severe Pain

AlzeCure Pharma AB (publ) Presents Disease-Modifying Data with NeuroRestore ACD856 At Alzheimer's Conference CTAD

AlzeCure Pharma AB (publ) Announces Japenese Patent Office Grants Patent Covering its Leading Candidate Drug ACD856

Alzecure Presents Clinical Phase Ii-Data with Acd440 for Neuropathic Pain At Pain Conference

AlzeCure Gets Presentation Accepted on Disease-Modifying Effects of Acd856 At Alzheimer's Conference

AlzeCure Pharma AB (publ) Presents Positive Phase II Clinical Data with ACD440 Against Neuropathic Pain at EFIC 2023 Conference

AlzeCure Pharma AB (publ) to Report Fiscal Year 2023 Final Results on Apr 04, 2024

New minor risk - Financial position

AlzeCure Pharma AB (publ) to Report Q4, 2023 Results on Feb 27, 2024

AlzeCure Pharma Publishes the Positive Clinical Results from the Phase I Trial of NeuroRestore ACD856 Against Alzheimer's

AlzeCure Pharma AB (Publ) Publishes New Disease Modifying Data with Neurorestore ACD856 Against Alzheimer's and Cognitive Disorders

Alzecure Announces Positive Phase IIa Clinical Study Data in Neuropathic Pain with the Non-Opioid ACD440

AlzeCure Pharma AB (publ) Appoints Janet Hoogstraate to its Board

Forecast to breakeven in 2025

Last Patient Included in Alzecure's Phase II Clinical Trial in Peripheral Neuropathic Pain with The Non-Opioid ACD440

AlzeCure Pharma AB (publ) Selects CD and Enters Next Development Phase with Alzstatin ACD680 against Alzheimer's

Alzecure Pharma AB (Publ) Gets Abstract Accepted on New Potential Disease-Modifying Effects of ACD856 Against Alzheimer's

AlzeCure Pharma AB (publ) Gets Late-Breaking Abstract on New Data with Alzheimer Project

Alzecure Pharma AB (Publ) Announces New Data on Alzstatin for Preventive Treatment Against Alzheimer's Presented At Alzheimer's Conference CTAD

Alzheimer Announces New Data Strengthening the Continued Clinical Development of NeuroRestore ACD856

AlzeCure Pharma AB (publ) Gets Abstract Accepted on Positive Clinical EEG Results with Alzheimer's Project NeuroRestore ACD856

AlzeCure Pharma AB (publ) Announces New Data from AlzeCure Demonstrate Potential Disease-Modifying Effects of NeuroRestore ACD856

AlzeCure Presents New Data on the Anti-Inflammatory Effects of its TrkA-NAM Pain Project at IASP 2022

AlzeCure's Alzheimer’s Project NeuroRestore ACD856 Shows Positive Effect on Brain Activity in Clinical Trial

AlzeCure Pharma AB (publ) Gets Abstract Accepted on Potential Neuroprotective Effects of NeuroRestore ACD856

AlzeCure Pharma AB Gets Abstract on New Clinical Study Data with NeuroRestore Accepted At the Alzheimer's Conference Aaic

AlzeCure Pharma AB (Publ) Announces Update on Clinical Phase I Study

AlzeCure Pharma AB (publ) Announces First Patient Included in its Phase II Clinical Trial in Neuropathic Pain with Non-Opioid ACD440

Alzecure Pharma AB (Publ)'s Abstract on Pain Project TrkA-NAM Accepted for Presentation At IASP 2022

AlzeCure Pharma AB (publ) Gets Approval to Start Phase II Clinical Trial with Non-Opioid Pain Project ACD440

AlzeCure Pharma AB (publ) Publishes New Data on Alzstatin from Alzheimer Conference

AlzeCure Publishes New Data on NeuroRestore and Acd856 from Alzheimer's Conference

Chief Executive Officer recently bought €16k worth of stock

Chief Executive Officer recently bought €16k worth of stock

Alzecure Pharma AB (Publ) Receives Positive Indicative Clinical Data with Acd856 in Development for Alzheimer's Disease

Alzecure Pharma AB (publ) Announces Moving Towards Phase IIa Clinical Trial with ACD440 Based on Guiding Response from the FDA

AlzeCure Pharma AB (publ) to Present Abstract at ECNP Conference on NeuroRestore Project's Potential in Depression

AlzeCure Pharma AB (publ) to Report Fiscal Year 2021 Results on Feb 24, 2022

AlzeCure Pharma AB (publ) to Report Q2, 2021 Results on Aug 25, 2021

New 90-day low: €0.74

New 90-day low: €0.77

AlzeCure Pharma AB (publ), Annual General Meeting, May 12, 2021

AlzeCure Pharma AB (publ) Receives Approval to Start Clinical Phase I Trial with ACD856 in Alzheimer's Disease

Chief Executive Officer recently bought €92k worth of stock

Alzecure Gets Abstract on the Neurorestore Platform Against Alzheimer's Accepted for Poster Presentation At CTAD

AlzeCure Pharma AB Provides Scientific Update on Alzheimer's Disease and the Alzstatin Project Platform

New 90-day high - €1.07

AlzeCure Pharma AB (publ) to Report Fiscal Year 2020 Results on Feb 28, 2021

New 90-day high - €0.76

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team